LIFU: Optimizing Parameters of Low-Intensity Focused Ultrasound for Cortical Modulation in Stroke Patients

Sponsor
Duke University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05016531
Collaborator
American Heart Association (Other)
90
1
1
26.6
3.4

Study Details

Study Description

Brief Summary

The purpose of this research study is to find out the optimal intensity and frequency of Low Intensity Focused Ultrasound (LIFU) that is safe and tolerable in people who have had a stroke.

Condition or Disease Intervention/Treatment Phase
  • Device: Low Intensity Focused Ultrasonic Stimulation
  • Device: Low Intensity Focused Ultrasonic Stimulation Frequency
N/A

Detailed Description

Aim 1 is to determine the optimal intensity of Low Intensity Focused Ultrasound stimulation (LIFUS) in stroke patients in terms of safety. We will investigate the optimal spatial-peak temporal-average intensity/ISPTA in the range of 0(or sham) W/cm2 to 8 W/cm2. Safety will be investigated by assessing clinically detectable signs and symptoms by monitoring vital signs and surveying subjects with a questionnaire before and after each stimulation session, and additionally by detecting subclinical neuronal injury using MRI/DWI. Aim 1 requires up to 72 subjects.

Aim 2 is to determine the optimal frequency of LIFU stimulation in stroke patients in terms of cortical excitability. Stroke subjects undergo each of the 5 frequency levels (0.35 MHz; 0.5 MHz; 0.75 MHz, 1.0 MHz and 1.5 MHz) on 5 different days with at least one day washout. The intensity (ISPTA) will set up at the level that is determined from Aim 1. Cortical excitability is measured by the amplitude of motor evoked potentials (MEPs) induced by Transcranial Magnetic Stimulation (TMS) from the Abductor Pollicis Brevis (ABP) muscle of the affected side. MEPs will be recorded pre- and post-stimulation to determine the optimal intensity for maximal cortical excitability from the hemisphere where the lesion is located. Aim 2 requires 18 subjects.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
90 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Optimizing Parameters of Low-Intensity Focused Ultrasound for Cortical Modulation in Stroke Patients
Actual Study Start Date :
Oct 11, 2021
Anticipated Primary Completion Date :
Aug 31, 2023
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Low Intensity Focused Ultrasonic Stimulation

There are different combinations of intensity and frequency with LIFUS

Device: Low Intensity Focused Ultrasonic Stimulation
Brain stimulation using ultrasonic stimulation in a sequence of increasing intensity (sham, 1 W/CM2, 2 W/CM2, 4 W/CM2, 6 W/CM2, 8 W/CM2)

Device: Low Intensity Focused Ultrasonic Stimulation Frequency
Brain stimulation using ultrasonic stimulation of intensity level determined from intervention 1 at progressively increasing frequency levels (0.35 MHz; 0.5 MHz; 0.75 MHz, 1.0 MHz and 1.5 MHz)

Outcome Measures

Primary Outcome Measures

  1. Safety Outcomes, as measured by the number of participants with a "major response" - Aim 1 of study [At any point during or immediately following intervention on day of LIFUS application]

    Safety outcomes are measured by "major response" which is pre-defined by any of the following event Second degree skin injury; Clinical seizure; New lesion on DWI sequence of MRI scan and the lesion not explained by any other cause(s) or decreased ADC under the transducer stimulating motor cortex area; Patient discontinues from the study due to any reason This is a 6+6 study design. Basically, 6 subjects are recruited at a given intensity level. Trial is stopped if ≥3/6 subjects at a given intensity level show major response. If ≤ 2 subjects shows major response, 6 more subjects are recruited to further test safety at the same intensity level; if ≤ 2/12 major response occurs, the intensity will be escalated to next higher level; if major response occurs ≥ 3/12 subjects, then the trial will terminate. The sequence for intensity escalation is sham > 1 W/cm2 > 2 W/cm2 > 4W/cm2 > 6W/cm2 > 8W/cm2.

  2. Cortical Excitability - Aim 2 of the study [Immediately after ultrasonic stimulation]

    Cortical excitability is measured by Motor evoked potential(MEP) amplitude using Transcranial Magnetic Stimulation. Mean changes on MEP ( Pre- Post- Ultrasonic Stimulation on the same day) is compared across 5 different stimulation frequency groups.

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. ≥ 21 years old of any gender and race;

  2. Clinical ischemic stroke (confirmed by CT or MRI) that occurred > 2 months ago;

  3. Predominantly unilateral motor impairment with FM-UE score ≤ 62/66;

  4. MEPs are inducible from a hand muscle on the affected side (i.e. Abductor Pollicis Brevis (APB) muscle).

Exclusion Criteria:
  1. Any concomitant neurological disorder affecting arm function;

  2. Documented history of severe dementia with or without medication before stroke;

  3. Subject is unable to do the motor learning practice at the baseline;

  4. Presence of any MRI/TMS/ultrasonic stimulation risk factors: an electrically, magnetically, or mechanically activated metal or nonmetal implant including cardiac pacemaker, intracerebral vascular clips, or any other electrically sensitive support system; non-fixed metal in any part of the body; pregnancy (the effect of TMS/ultrasonic stimulation on the fetus is unknown); no history of seizure before or after the stroke; preexisting scalp lesion or wound or bone defect or hemicraniectomy.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Duke University Hospital Durham North Carolina United States 27710

Sponsors and Collaborators

  • Duke University
  • American Heart Association

Investigators

  • Principal Investigator: Wayne Feng, Duke Health

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Duke University
ClinicalTrials.gov Identifier:
NCT05016531
Other Study ID Numbers:
  • Pro00106556
First Posted:
Aug 23, 2021
Last Update Posted:
Jul 15, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Duke University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 15, 2022